Details about Tomas Philipson

Homepage:	http://harrisschool.uchicago.edu/faculty/web-pages/tomas-philipson.asp
Workplace:	Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, (more information at EDIRC) National Bureau of Economic Research (NBER), (more information at EDIRC) Harris School of Public Policy, University of Chicago, (more information at EDIRC)

Access statistics for papers by Tomas Philipson.

Last updated 2024-02-18. Update your information in the RePEc Author Service.

Short-id: pph37

---

Jump to Journal Articles Books Chapters

Working Papers

2017

1. Sharing R&D Risk in Healthcare via FDA Hedges
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (7)
   See also Journal Article Sharing R&D Risk in Healthcare via FDA Hedges, The Review of Corporate Finance Studies, Society for Financial Studies (2022) View citations (4) (2022)

2016

2. How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (1)
   See also Journal Article How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations, American Journal of Health Economics, University of Chicago Press (2018) View citations (6) (2018)

2014

3. Financial Health Economics
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (2)
   See also Journal Article Financial Health Economics, Econometrica, Econometric Society (2016) View citations (30) (2016)
4. Health Care Adherence and Personalized Medicine
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (8)

2013

5. Adjusting Measures of Economic Output for Health: Is the Business Cycle Countercyclical?
   Working Papers, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State
6. Adjusting National Accounting for Health: Is the Business Cycle Countercyclical?
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (3)
7. Economic Analysis of Risk and Uncertainty induced by Health Shocks: A Review and Extension
   NBER Working Papers, National Bureau of Economic Research, Inc
8. International Health Economics
   Working Papers, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State View citations (1)
   Also in NBER Working Papers, National Bureau of Economic Research, Inc (2013) View citations (2)

2012

9. Public Liabilities and Health Care Policy
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (2)

2011

10. Can Medical Progress be Sustained? Implications of the Link Between Development and Output Markets
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (11)
    Also in Working Papers, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State (2011)

2010

11. Terminal Care and The Value of Life Near Its End
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (18)
12. The Impact of Comparative Effectiveness Research on Health and Health Care Spending
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (11)
    See also Journal Article The impact of comparative effectiveness research on health and health care spending, Journal of Health Economics, Elsevier (2011) View citations (13) (2011)

2009

13. An Economic Evaluation of the War on Cancer
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (5)
    See also Journal Article An economic evaluation of the war on cancer, Journal of Health Economics, Elsevier (2010) View citations (23) (2010)
14. Endogenous Cost-Effectiveness Analysis in Health Care Technology Adoption
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (20)
    See also Journal Article Endogenous cost-effectiveness analysis and health care technology adoption, Journal of Health Economics, Elsevier (2013) View citations (14) (2013)
15. The Effects of Product Liability Exemption in the Presence of the FDA
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (2)
    See also Chapter The Effects of Product Liability Exemption in the Presence of the FDA, NBER Chapters, National Bureau of Economic Research, Inc (2010) View citations (3) (2010)

2008

16. Is the Obesity Epidemic a Public Health Problem? A Decade of Research on the Economics of Obesity
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (53)
17. The Value of Life in General Equilibrium
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (8)

2007

18. Cost-Benefit Analysis of the FDA: The Case of the Prescription Drug User Fee Acts
    Working Papers, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State
    See also Journal Article Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts, Journal of Public Economics, Elsevier (2008) View citations (15) (2008)
19. Integrated Insurance Design in the Presence of Multiple Medical Technologies
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (58)
    See also Journal Article Integrated Insurance Design in the Presence of Multiple Medical Technologies, American Economic Review, American Economic Association (2007) View citations (58) (2007)
20. Intellectual Property and Marketing
    Working Papers, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State
    Also in NBER Working Papers, National Bureau of Economic Research, Inc (2006) View citations (10)
21. Is the Food and Drug Administration Safe and Effective?
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (1)
    Also in Working Papers, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State (2007)
    See also Journal Article Is the Food And Drug Administration Safe And Effective?, Journal of Economic Perspectives, American Economic Association (2008) View citations (15) (2008)
22. The Value of Life Near its End and Terminal Care
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (12)
    Also in Levine's Working Paper Archive, David K. Levine (2007) View citations (13)

2006

23. Antitrust in the Not-For-Profit Sector
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (10)
    Also in NBER Working Papers, National Bureau of Economic Research, Inc (2001) View citations (6)
    See also Journal Article Antitrust in the Not-for-Profit Sector, Journal of Law and Economics, University of Chicago Press (2009) View citations (23) (2009)
24. Health Care, Technological Change, and Altruistic Consumption Externalities
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (3)
25. Surplus Appropriation from R&D and Health Care Technology Assessment Procedures
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (11)
    Also in Public Economics, University Library of Munich, Germany (2005) View citations (3)

2005

26. Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (4)
    Also in Working Papers, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State (2005)
27. Intellectual Property & External Consumption Effects: Generalizations From Health Care Markets
    Working Papers, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State
    Also in Working Papers, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State (2005)
28. Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (7)
    See also Journal Article Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs, Forum for Health Economics & Policy, De Gruyter (2006) View citations (28) (2006)

2004

29. Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (5)
    See also Chapter Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process, NBER Chapters, National Bureau of Economic Research, Inc (2005) View citations (1) (2005)
    Journal Article Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process, Forum for Health Economics & Policy, De Gruyter (2005) View citations (1) (2005)

2003

30. Intellectual Property & External Consumption Effects: Generalizations from Pharmaceutical Markets
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (9)
31. The Quantity and Quality of Life and the Evolution of World Inequality
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (44)
    See also Journal Article The Quantity and Quality of Life and the Evolution of World Inequality, American Economic Review, American Economic Association (2005) View citations (483) (2005)

2002

32. The Dual Effects of Intellectual Property Regulations: Within- and Between- Patent Competition in the US Pharmaceuticals Industry
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (31)
    Also in Working Papers, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State (2002)
    See also Journal Article The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the U.S. Pharmaceuticals Industry, Journal of Law and Economics, University of Chicago Press (2002) View citations (30) (2002)
33. The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the US
    Working Papers, Harris School of Public Policy Studies, University of Chicago
34. The Growth of Obesity and Technological Change: A Theoretical and Empirical Examination
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (248)
    Also in Working Papers, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State (2002) View citations (2)
    Working Papers, Harris School of Public Policy Studies, University of Chicago (2002)

2000

35. External Treatment Effects and Program Implementation Bias
    NBER Technical Working Papers, National Bureau of Economic Research, Inc View citations (17)
    Also in Working Papers, Harris School of Public Policy Studies, University of Chicago (1999)
36. Merit Motives & Government Intervention: Public Finance in Reverse
    Working Papers, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State View citations (1)
37. Merit Motives and Government Intervention: Public Finance in Reverse
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (11)
    Also in University of Chicago - Population Research Center, Chicago - Population Research Center View citations (9)

1999

38. Aging and the Growth of Long-Term Care
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (7)
    Also in Working Papers, Harris School of Public Policy Studies, University of Chicago (1999)
39. Economic Epidemiology and Infectious Diseases
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (31)
    See also Chapter Economic epidemiology and infectious diseases, Handbook of Health Economics, Elsevier (2000) View citations (121) (2000)
40. The Long-Run Growth in Obesity as a Function of Technological Change
    Working Papers, Harris School of Public Policy Studies, University of Chicago
    Also in NBER Working Papers, National Bureau of Economic Research, Inc (1999) View citations (134)

1998

41. Data MArkets and OPtimal Sample Size Determination
    DELTA Working Papers, DELTA (Ecole normale supérieure)
42. Nonprofit Production and Competition
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (44)
43. Pricing and R&D with Related Margins
    DELTA Working Papers, DELTA (Ecole normale supérieure)
44. The Rise in Old Age Longevity and the Market for Long-Term Care
    Working Papers, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State
    Also in NBER Working Papers, National Bureau of Economic Research, Inc (1998) View citations (5)
    See also Journal Article The Rise in Old-Age Longevity and the Market for Long-Term Care, American Economic Review, American Economic Association (2002) View citations (52) (2002)

1997

45. An Empirical Examination of Information Barriers to Trade in Insurance
    Working Papers, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State
    Also in NBER Working Papers, National Bureau of Economic Research, Inc (1996) View citations (12)
    See also Journal Article An Empirical Examination of Information Barriers to Trade in Insurance, American Economic Review, American Economic Association (1999) View citations (230) (1999)
46. Consumption vs. Production of Insurance
    NBER Working Papers, National Bureau of Economic Research, Inc
47. Health investment complementarities under competing risks
    Economics Working Papers, Department of Economics and Business, Universitat Pompeu Fabra View citations (2)
48. Observational Agency and Supply-Side Econometrics
    NBER Technical Working Papers, National Bureau of Economic Research, Inc
49. The Future of Old-Age Longevity: Competitive Pricing of Morality Contingent Claims
    Working Papers, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State
    Also in NBER Working Papers, National Bureau of Economic Research, Inc (1997) View citations (3)

1996

50. Mortality Contingent Claims, Health Care, and Social Insurance
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (2)
    Also in Working Papers, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State (1996)
51. The Private Demand for Information and the Effects of Public Testing Programs: The Case of HIV
    Working Papers, Yale - Economic Growth Center View citations (1)

1995

52. Death, Tetanus and Aerobics: The Evaluation of Disease-Specific Health Interventions
    CEPR Discussion Papers, C.E.P.R. Discussion Papers
    Also in Economics Working Papers, Department of Economics and Business, Universitat Pompeu Fabra (1995)
53. Disease Complementarities and the Evaluation of Public Health Interventions
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (1)
54. Disease Eradication: Private vs. Public Vaccination
    DELTA Working Papers, DELTA (Ecole normale supérieure)
55. Rational Epidemics and their Public Control
    DELTA Working Papers, DELTA (Ecole normale supérieure)
    See also Journal Article Rational Epidemics and Their Public Control, International Economic Review, Department of Economics, University of Pennsylvania and Osaka University Institute of Social and Economic Research Association (1996) View citations (169) (1996)

1994

56. Will the AIDS Epidemic be Self-Limiting? Evidence on the Responsiveness of the Demand for Condoms to the Prevalence of AIDS
    Working Papers, Harris School of Public Policy Studies, University of Chicago
    Also in University of Chicago - Population Research Center, Chicago - Population Research Center View citations (4)

Undated

57. Estimating the Extent of Trade Under Incomplete Information: The Case of HIV
    University of Chicago - Population Research Center, Chicago - Population Research Center
58. Is Health Care Technology Over-Approved? A Meta-Analysis of Revealed Preference
    University of Chicago - Population Research Center, Chicago - Population Research Center
59. Nonprofit Production
    University of Chicago - Population Research Center, Chicago - Population Research Center View citations (7)
60. Self-Interested Treatment Evaluation in Experiments
    University of Chicago - Population Research Center, Chicago - Population Research Center

Journal Articles

2022

1. Sharing R&D Risk in Healthcare via FDA Hedges
   (Bank lines of credit as contingent liquidity: Covenant violations and their implications)
   The Review of Corporate Finance Studies, 2022, 11, (4), 880-922 View citations (4)
   See also Working Paper Sharing R&D Risk in Healthcare via FDA Hedges, NBER Working Papers (2017) View citations (7) (2017)

2019

2. Labor Markets in Statistics: The Subject Supply Effect in Medical R&D
   Journal of Human Capital, 2019, 13, (2), 293 - 340

2018

3. How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations
   American Journal of Health Economics, 2018, 4, (4), 433-453 View citations (6)
   Also in American Journal of Health Economics, 2018, 4, (4), 433-453 (2018) View citations (6)
   See also Working Paper How Does Technological Change Affect Quality-Adjusted Prices in Health Care? Systematic Evidence from Thousands of Innovations, NBER Working Papers (2016) View citations (1) (2016)

2017

4. Defining Value: The Need for a Longer, Broader View
   PharmacoEconomics, 2017, 35, (7), 669-672

2016

5. Financial Health Economics
   Econometrica, 2016, 84, 195-242 View citations (30)
   See also Working Paper Financial Health Economics, NBER Working Papers (2014) View citations (2) (2014)
6. Quantifying Gains in the War on Cancer Due to Improved Treatment and Earlier Detection
   Forum for Health Economics & Policy, 2016, 19, (1), 141-156

2014

7. A Cost-Benefit Analysis of Using Evidence of Effectiveness in Terms of Progression Free Survival in Making Reimbursement Decisions on New Cancer Therapies
   Forum for Health Economics & Policy, 2014, 17, (1), 21-52
8. Can Oral Nutritional Supplements Improve Medicare Patient Outcomes in the Hospital?
   Forum for Health Economics & Policy, 2014, 17, (2), 131-151
9. HETEROGENEITY IN ACTION: THE ROLE OF PASSIVE PERSONALIZATION IN COMPARATIVE EFFECTIVENESS RESEARCH
   Health Economics, 2014, 23, (3), 359-373 View citations (6)
10. RESPONSE TO EPSTEIN'S COMMENT ON “HETEROGENEITY IN ACTION”
    Health Economics, 2014, 23, (3), 376-378

2013

11. Endogenous cost-effectiveness analysis and health care technology adoption
    Journal of Health Economics, 2013, 32, (1), 172-180 View citations (14)
    See also Working Paper Endogenous Cost-Effectiveness Analysis in Health Care Technology Adoption, NBER Working Papers (2009) View citations (20) (2009)
12. Quantifying the Value of Personalized Medicines: Evidence from COX-2 Inhibitors
    Forum for Health Economics & Policy, 2013, 16, (1), 101-122 View citations (2)
13. Should Global Health be Tailored Toward the Rich? Altruism and Efficient R&D for Neglected Diseases
    Forum for Health Economics & Policy, 2013, 16, (1), 83-99
14. The Value of Diagnostic Testing in Personalized Medicine
    Forum for Health Economics & Policy, 2013, 16, (2), S87-S99 View citations (3)

2012

15. A Reexamination of the Costs of Medical R&D Regulation
    Forum for Health Economics & Policy, 2012, 15, (1), 1-28 View citations (1)
16. Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets
    Journal of Law and Economics, 2012, 55, (1), 151 - 187 View citations (15)
17. The Option Value of Innovation
    Forum for Health Economics & Policy, 2012, 15, (1), 19 View citations (3)

2011

18. The impact of comparative effectiveness research on health and health care spending
    Journal of Health Economics, 2011, 30, (4), 695-706 View citations (13)
    See also Working Paper The Impact of Comparative Effectiveness Research on Health and Health Care Spending, NBER Working Papers (2010) View citations (11) (2010)

2010

19. Altruism and Innovation in Health Care
    Journal of Law and Economics, 2010, 53, (3), 497 - 518 View citations (3)
20. An economic evaluation of the war on cancer
    Journal of Health Economics, 2010, 29, (3), 333-346 View citations (23)
    See also Working Paper An Economic Evaluation of the War on Cancer, NBER Working Papers (2009) View citations (5) (2009)
21. Erratum: Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA
    Health Economics, 2010, 19, (12), 1510-1510 View citations (5)
22. External Costs of Risky Health Behaviors Associated with Leading Actual Causes of Death in the U.S.: A Review of the Evidence and Implications for Future Research
    IJERPH, 2010, 7, (6), 1-13
23. Geographic Variation in Health Care: The Role of Private Markets
    Brookings Papers on Economic Activity, 2010, 41, (1 (Spring)), 325-361 View citations (17)
24. The Contributions of Improved Therapy and Earlier Detection to Cancer Survival Gains, 1988-2000
    Forum for Health Economics & Policy, 2010, 13, (2), 22 View citations (5)
25. Valuing health technologies at nice: recommendations for improved incorporation of treatment value in HTA
    Health Economics, 2010, 19, (10), 1109-1116 View citations (6)

2009

26. Antitrust in the Not-for-Profit Sector
    Journal of Law and Economics, 2009, 52, (1), 1-18 View citations (23)
    See also Working Paper Antitrust in the Not-For-Profit Sector, NBER Working Papers (2006) View citations (10) (2006)
27. The growth of obesity and technological change
    Economics & Human Biology, 2009, 7, (3), 283-293 View citations (167)
28. `Me-Too' Innovation in Pharmaceutical Markets
    Forum for Health Economics & Policy, 2009, 12, (1), 21 View citations (7)
    See also Chapter "Me-Too" Innovation in Pharmaceutical Markets, NBER Chapters, 2009 (2009) View citations (4) (2009)

2008

29. Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts
    Journal of Public Economics, 2008, 92, (5-6), 1306-1325 View citations (15)
    See also Working Paper Cost-Benefit Analysis of the FDA: The Case of the Prescription Drug User Fee Acts, Working Papers (2007) (2007)
30. Cost-effectiveness analysis and innovation
    Journal of Health Economics, 2008, 27, (5), 1224-1236 View citations (26)
31. Is the Food And Drug Administration Safe And Effective?
    Journal of Economic Perspectives, 2008, 22, (1), 85-102 View citations (15)
    See also Working Paper Is the Food and Drug Administration Safe and Effective?, NBER Working Papers (2007) View citations (1) (2007)
32. Is the Obesity Epidemic a Public Health Problem? A Review of Zoltan J. Acs and Alan Lyles's Obesity, Business and Public Policy
    Journal of Economic Literature, 2008, 46, (4), 974-82 View citations (41)

2007

33. Commentary
    Managerial and Decision Economics, 2007, 28, (4-5), 453-454
34. Commentary
    Managerial and Decision Economics, 2007, 28, (4-5), 437-438
35. Commentary
    Managerial and Decision Economics, 2007, 28, (4-5), 467-468
36. Integrated Insurance Design in the Presence of Multiple Medical Technologies
    American Economic Review, 2007, 97, (2), 427-432 View citations (58)
    See also Working Paper Integrated Insurance Design in the Presence of Multiple Medical Technologies, NBER Working Papers (2007) View citations (58) (2007)
37. Labor Supply and Weight
    Journal of Human Resources, 2007, 42, (1) View citations (65)
38. The institute of medicine report on the FDA: where is the science?
    Health Economics, 2007, 16, (3), 219-221

2006

39. The nonprofit sector and industry performance
    Journal of Public Economics, 2006, 90, (8-9), 1681-1698 View citations (116)
40. Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs
    Forum for Health Economics & Policy, 2006, 9, (2), 33 View citations (28)
    See also Working Paper Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs, NBER Working Papers (2005) View citations (7) (2005)

2005

41. Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process
    Forum for Health Economics & Policy, 2005, 8, (1), 25 View citations (1)
    See also Chapter Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process, NBER Chapters, 2005 (2005) View citations (1) (2005)
    Working Paper Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process, NBER Working Papers (2004) View citations (5) (2004)
42. The Quantity and Quality of Life and the Evolution of World Inequality
    American Economic Review, 2005, 95, (1), 277-291 View citations (483)
    See also Working Paper The Quantity and Quality of Life and the Evolution of World Inequality, NBER Working Papers (2003) View citations (44) (2003)
43. Welfare-Enhancing Technological Change and the Growth of Obesity
    American Economic Review, 2005, 95, (2), 253-257 View citations (151)

2002

44. Pricing and R&D When Consumption Affects Longevity
    RAND Journal of Economics, 2002, 33, (1), 85-95 View citations (3)
45. The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the U.S. Pharmaceuticals Industry
    Journal of Law and Economics, 2002, 45, (S2), 643-672 View citations (30)
    See also Working Paper The Dual Effects of Intellectual Property Regulations: Within- and Between- Patent Competition in the US Pharmaceuticals Industry, NBER Working Papers (2002) View citations (31) (2002)
46. The Regulation of Medical Innovation and Pharmaceutical Markets
    Journal of Law and Economics, 2002, 45, (S2), 583-586 View citations (1)
47. The Rise in Old-Age Longevity and the Market for Long-Term Care
    American Economic Review, 2002, 92, (1), 295-306 View citations (52)
    See also Working Paper The Rise in Old Age Longevity and the Market for Long-Term Care, Working Papers (1998) (1998)

2001

48. Data Markets, Missing Data, and Incentive Pay
    Econometrica, 2001, 69, (4), 1099-1111 View citations (13)
49. Managed Care and the Quality of Health Care: A Misguided Debate?
    The Journal of Legal Studies, 2001, 30, (2), 753-58
50. Public Financing and the Market for Long-Term Care
    Forum for Health Economics & Policy, 2001, 4, (1), 19
    See also Chapter Public Financing and the Market for Long-Term Care, NBER Chapters, 2001, 77-94 (2001) (2001)
51. The world‐wide growth in obesity: an economic research agenda
    Health Economics, 2001, 10, (1), 1-7 View citations (92)

2000

52. The Impact of Public Testing for Human Immunodeficiency Virus
    Journal of Human Resources, 2000, 35, (3), 419-446 View citations (45)

1999

53. An Empirical Examination of Information Barriers to Trade in Insurance
    American Economic Review, 1999, 89, (4), 827-846 View citations (230)
    See also Working Paper An Empirical Examination of Information Barriers to Trade in Insurance, Working Papers (1997) (1997)
54. Longevity Complementarities under Competing Risks
    American Economic Review, 1999, 89, (5), 1358-1371 View citations (59)
55. Measurement errors: A principal investigator-agent approach
    Journal of Econometrics, 1999, 91, (2), 273-298 View citations (13)

1998

56. Old-Age Longevity and Mortality-Contingent Claims
    Journal of Political Economy, 1998, 106, (3), 551-573 View citations (111)
57. Subject Evaluation in Social Experiments
    Econometrica, 1998, 66, (2), 381-408 View citations (17)

1997

58. Data Markets and the Production of Surveys
    The Review of Economic Studies, 1997, 64, (1), 47-72 View citations (25)
59. Disease Eradication: Private versus Public Vaccination
    American Economic Review, 1997, 87, (1), 222-30 View citations (145)
60. Multiple-output agency incentives in data production: experimental evidence
    European Economic Review, 1997, 41, (3-5), 961-970 View citations (4)
61. The evaluation of new health care technology: The labor economics of statistics
    Journal of Econometrics, 1997, 76, (1-2), 375-395 View citations (7)

1996

62. An empirical examination of the implications of assortative matching on the incidence of HIV
    Journal of Health Economics, 1996, 15, (6), 735-749 View citations (9)
63. Equilibrium and Efficiency in an Organized Vote Market
    Public Choice, 1996, 89, (3-4), 245-65 View citations (29)
64. Private Vaccination and Public Health: An Empirical Examination for U.S. Measles
    Journal of Human Resources, 1996, 31, (3), 611-630 View citations (58)
65. Rational Epidemics and Their Public Control
    International Economic Review, 1996, 37, (3), 603-24 View citations (169)
    See also Working Paper Rational Epidemics and their Public Control, DELTA Working Papers (1995) (1995)
66. The Economic Epidemiology of Crime
    Journal of Law and Economics, 1996, 39, (2), 405-33 View citations (33)
67. The Responsiveness of the Demand for Condoms to the Local Prevalence of AIDS
    Journal of Human Resources, 1996, 31, (4), 869-897 View citations (68)
68. `RATIONAL CHOICE, PUBLIC POLICY AND AIDS'
    Rationality and Society, 1996, 8, (4), 498-502

1995

69. A Theoretical and Empirical Investigation of the Effects of Public Health Subsidies for STD Testing
    The Quarterly Journal of Economics, 1995, 110, (2), 445-474 View citations (29)
70. The welfare loss of disease and the theory of taxation
    Journal of Health Economics, 1995, 14, (3), 387-395 View citations (12)

1994

71. Public Spending on AIDS Education: An Economic Analysis
    Journal of Law and Economics, 1994, 37, (1), 17-38 View citations (18)

1993

72. Social Welfare and Measurement of Segregation
    Journal of Economic Theory, 1993, 60, (2), 322-334 View citations (14)

1992

73. Desegregation and Social Monopoly Pricing
    Rationality and Society, 1992, 4, (2), 189-198
74. Evaluating an Argument for Affirmative Action
    Rationality and Society, 1992, 4, (3), 360-364

1991

75. Dynamic information release
    Journal of Economics, 1991, 53, (2), 205-213

Books

2010

1. Health and Wealth Disparities in the United States
   Books, American Enterprise Institute

Chapters

2018

1. The Economic Value and Pricing of Personalized Medicine
   A chapter in Economic Dimensions of Personalized and Precision Medicine, 2018, pp 9-19

2012

2. Economics of Obesity
   Chapter 7 in The Elgar Companion to Health Economics, Second Edition, 2012
   Also in Chapter 7 in The Elgar Companion to Health Economics, 2006 (2006)

2010

3. The Effects of Product Liability Exemption in the Presence of the FDA
   A chapter in Regulation vs. Litigation: Perspectives from Economics and Law, 2010, pp 137-163 View citations (3)
   See also Working Paper The Effects of Product Liability Exemption in the Presence of the FDA, National Bureau of Economic Research, Inc (2009) View citations (2) (2009)

2009

4. "Me-Too" Innovation in Pharmaceutical Markets
   A chapter in Frontiers in Health Policy Research, volume 12, 2009 View citations (4)
   See also Journal Article `Me-Too' Innovation in Pharmaceutical Markets, De Gruyter (2009) View citations (7) (2009)

2005

5. Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process
   A chapter in Frontiers in Health Policy Research, Volume 8, 2005 View citations (1)
   See also Journal Article Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process, De Gruyter (2005) View citations (1) (2005)
   Working Paper Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process, National Bureau of Economic Research, Inc (2004) View citations (5) (2004)

2003

6. Theories of Firm Behavior in the Nonprofit Sector. A Synthesis and Empirical Evaluation
   A chapter in The Governance of Not-for-Profit Organizations, 2003, pp 181-216 View citations (42)

2002

7. A direct test of the 'lemons' model: the market for used pickup trucks
   Chapter 13 in Market Failure or Success, 2002

2001

8. Medical Care Output and Productivity in the Nonprofit Sector
   A chapter in Medical Care Output and Productivity, 2001, pp 119-140 View citations (2)
9. Public Financing and the Market for Long-Term Care
   A chapter in Frontiers in Health Policy Research, Volume 4, 2001, pp 77-94
   See also Journal Article Public Financing and the Market for Long-Term Care, De Gruyter (2001) (2001)

2000

10. Asymmetric Information and the Not-for-Profit Sector Does Its Output Sell a a Premium?
    A chapter in The Changing Hospital Industry: Comparing Not-for-Profit and For-Profit Institutions, 2000, pp 325-356 View citations (8)
11. Economic epidemiology and infectious diseases
    Chapter 33 in Handbook of Health Economics, 2000, vol. 1, pp 1761-1799 View citations (121)
    See also Working Paper Economic Epidemiology and Infectious Diseases, National Bureau of Economic Research, Inc (1999) View citations (31) (1999)